Skip to main
FULC
FULC logo

FULC Stock Forecast & Price Target

FULC Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Fulcrum Therapeutics Inc. is positioned for significant revenue growth, with projections estimating revenues approaching $560 million by 2028, primarily driven by advancements in the sickle cell disease market where few treatment options exist. Clinical data has demonstrated that the company’s lead candidate, pociredir, effectively increases fetal hemoglobin levels and improves key health metrics, such as a 44% response rate in patients achieving notable increases in total hemoglobin, which is linked to better survival outcomes. Furthermore, improvements in red blood cell health, including substantial reductions in biomarkers of hemolysis, support the therapeutic effectiveness of their treatments, enhancing the company’s prospects in the biopharmaceutical space.

Bears say

Fulcrum Therapeutics faces a negative outlook largely due to concerns over its weaker SCPC profile, which raises doubts about the potential for regulatory approval based solely on hemoglobin correction. The company has indicated that the early patients in the 20mg cohort exhibited lower baseline HbF levels, further complicating the prospects for successful clinical outcomes and commercialization. Additionally, any negative developments regarding trial readouts or regulatory submissions could significantly hinder Fulcrum's market potential and competitive positioning.

FULC has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fulcrum Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fulcrum Therapeutics Inc (FULC) Forecast

Analysts have given FULC a Buy based on their latest research and market trends.

According to 6 analysts, FULC has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fulcrum Therapeutics Inc (FULC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.